Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma

Cancer

Volumn 77, Issue 12, 1996, Pages 2458-2463

  Hainsworth, John D ^a,b   Stroup, Steven L ^a   Greco, F Anthony ^a  

^a CENTENNIAL MEDICAL CENTER   (United States)

^b Sarah Cannon Minnie Pearl Cancer C   (United States)

Author keywords

carboplatin; etoposide; extensive stage; limited stage; paclitaxel; small cell lung carcinoma

Indexed keywords

CARBOPLATIN; ETOPOSIDE; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; ESOPHAGITIS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OUTPATIENTS; PACLITAXEL; SURVIVAL ANALYSIS;

EID: 0030028443     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960615)77:12<2458::AID-CNCR7>3.0.CO;2-I     Document Type: Article

References (22)

1. Ihde DC, Pass HI, Glatstein EJ. Small cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th edition. Philadelphia: JB Lippincott, 1993:723-59.
2. Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994;12:2022-34.
3. Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 1993;11:336-44.
4. Gatzemeier U, Hossfeld DK, Neuhauss R, Reck M, Achterrath W, Lenaz L. Phase II and III studies with carboplatin in small cell lung cancer. Semin Oncol 1992;19(Suppl 2):28-36.
5. Kosmidis PA, Samantas E, Fountzilas G, Pavlidis N, Apostolopoulou F, Skarlos D. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Semin Oncol 1994;21(Suppl 6):23-30.
6. Ettinger DS, Finkelstein DM, Sarma RP, Johnson DH. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995;13:1430-5.
7. Kirschling RJ, Jung SH, Jett JR. A phase II trial of taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1994;13:326.
8. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, Van der Burg MEL, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusions. J Clin Oncol 1994;12:2654-66.
9. Hainsworth JD, Greco FA. Paclitaxel administered by one-hour infusion: preliminary results of a phase I/II trial comparing two schedules. Cancer 1994;74:1377-82.
10. Hainsworth JD, Raefsky EL, Thomas M, Greco FA. Paclitaxel administered by 1-hour infusion: phase I/II study comparing two schedules of administration. Cancer J Sci Am 1995; 1:281-7.
11. Jelliffe RW. Creatinine clearance:bedside estimate [letter]. Ann Intern Med 1973;79(4):604-5.
12. Hainsworth JD, Thompson DS, Greco FA. Paclitaxel by one-hour infusion:an active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995;13:1609-14.
13. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-70.
14. Vafai D, Israel V, Zaretsky S, Natale RB. Phase I/II trial of combination carboplatin and taxol in non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1995; 14:352.
15. Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase II trial. J Clin Oncol 1990;8:1613-7.
16. Clark PI, Cottier B. The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small-cell lung cancer. Semin Oncol 1992;19(Suppl 14):36-9.
17. Carney DN, Grogan L, Smit EF, Harford P, Berendsen HH, Postmus PE. Single-agent oral etoposide for elderly small-cell lung cancer patients. Semin Oncol 1991;17(Suppl 2):49-53.
18. Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, et al. Duration of chemotherapy in small cell lung cancer. A Cancer Research Campaign trial. Br J Cancer 1989;59:578-83.
19. Splinter TAW, EORTC Lung Cancer Cooperative Group. Induction versus induction plus maintenance chemotherapy in small cell lung cancer: definitive evaluation [abstract]. Proc Am Soc Clin Oncol 1988;7:202.
20. Bleehan NM, Payers PM, Girling DJ. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small cell lung cancer. Br J Cancer 1989;59:584-90.
21. Bunn PA Jr, Kelly K. Prophylactic cranial irradiation for patients with small-cell lung cancer. J Natl Cancer Inst 1985; 87:161-2.
22. Arriagada R, Le Chevalier T, Borie F, Riviere A, Chomy P, Monnet I, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995;87:183-90.